Prelude Therapeutics presents first data on PRT12396, a JAK2V617F-selective JH2 inhibitor with potential for myeloproliferative neoplasms. The company is on track for IND filing in Q1 2026. Additionally, a mutant calreticulin (mCALR) targeted degrader antibody conjugate (DAC) with a novel CDK9 degrader payload was disclosed. JAK2V617F and mCALR are key driver mutations in MPN patients. The JAK2V617F inhibitor program has shown promising preclinical results, while the mCALR degrader antibody conjugates program aims for disease modification. Both programs were presented at ASH. Prelude aims to bring innovative therapies to MPN patients with a focus on precision oncology.

Read more at GlobeNewswire: Prelude Therapeutics Presents Data at the 2025 ASH Annual